Tick-borne encephalitis virus neutralization by high dose intravenous immunoglobulin

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00027162%3A_____%2F17%3AN0000108" target="_blank" >RIV/00027162:_____/17:N0000108 - isvavai.cz</a>

Alternative codes found

RIV/60077344:_____/17:00474338 RIV/60076658:12310/17:43895486

Result on the web

<a href="http://www.sciencedirect.com/science/article/pii/S1877959X16302151" target="_blank" >http://www.sciencedirect.com/science/article/pii/S1877959X16302151</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.ttbdis.2016.11.007" target="_blank" >10.1016/j.ttbdis.2016.11.007</a>

Result language

angličtina

Original language name

Tick-borne encephalitis virus neutralization by high dose intravenous immunoglobulin

Original language description

Tick-borne encephalitis (TBE) is a potentially lethal neuroinfection in humans, caused by TBE virus (TBEV). Currently, there are no approved therapeutic agents to treat TBE. Previously, it was suggested that application of high dose intravenous immunoglobulin (IVIG) may pose potentially successful treatment for severe cases of TBE. In this study, we determined the titers of TBEV-neutralizing antibodies in two IVIG lots originating from the same manufacturer, and tested their ability to treat a lethal TBEV-infection in a mouse model. Using an in vitro assay, more than 100-fold difference in TBEV-neutralizing capacity was demonstrated between the two individual IVIG lots. High TBEV-neutralizing activity of IVIG containing TBEV-specific antibody was confirmed in two different human neural cell lines, but IVIG without TBEV-specific antibodies had no or little effect on virus titers in the culture. In TBEV-infected mice, 90% of protection was achieved when the mice were treated with IVIG containing higher titers of TBEV-specific antibodies, whereas no immunotherapeutic effect was seen when mice were treated with IVIG without TBEV-specific antibodies. No antibody-dependent enhancement of TBEV infectivity induced by cross-reactive antibodies or by virus-specific antibodies at neutralizing or sub-neutralizing levels was observed either in cell culture or in TBEV-infected mice treated with any of the IVIG preparations. The results indicate that IVIG lots with high TBEV antibody titers might represent a post-exposure prophylaxis or first-line effective therapy of patients with a severe form of TBE.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

10607 - Virology

Project

Result was created during the realization of more than one project. More information in the Projects tab.

Continuities

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2017

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Ticks and Tick-borne Diseases

ISSN

1877-959X

e-ISSN

—

Volume of the periodical

8

Issue of the periodical within the volume

2

Country of publishing house

DE - GERMANY

Number of pages

6

Pages from-to

253-258

UT code for WoS article

000393256700008

EID of the result in the Scopus database

—